Clinical trials: CGM
Diabetes Mellitus
Effectiveness and Safety Study of the DexCom™ G4 Continuous Glucose Monitoring System
The purpose of this study is to evaluate the safety and effectiveness of the G4 System when worn for up to 7-days by subjects >18 years-old with diabetes mellitus requiring insulin.
- Trial name
- NCT01111370
- Testing
- DexCom™ G4 Continuous Glucose Monitoring System
- Volunteers
- 60 people
- Sponsor
- DexCom, Inc.
Type 1 Diabetes Mellitus, Pregnancy
Orchestra Pregnancy Observational Study in Poland
The aim of this project is to document the use of insulin pump therapy (CSII), including sensor augmented pump therapy (SAP), before, during and after pregnancy in women with type 1 Diabetes Mellitus benefiting from the Orchestra…
- Trial name
- NCT01779141
- Where
- 24 sites in Poland
- Volunteers
- 481 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes
ADvanced Hybrid Closed Loop Study in Adult Population With Type 1 Diabetes
The purpose of this study evaluate the safety and efficacy of the Advanced Hybrid Closed Loop (AHCL) system in sub-optimally controlled patients with T1D, in comparison with Multiple Daily Injection (MDI) therapy with Flash…
- Trial name
- ADAPT (NCT04235504)
- Testing
- MDI, AHCL
- Where
- 14 sites in France, Germany and 1 more
- Volunteers
- 122 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus
A French Study to Evaluate the Usefulness of an Implantable Continuous Glucose Monitoring (CGM) Sensor to Improve Glycemic Control in Participants With Diabetes Mellitus
This study will be conducted in France and will evaluate the usefulness of using a long-term subcutaneously inserted continuous glucose monitoring (CGM) sensor (the Eversense XL CGM System) to improve glycemic control in patients…
- Trial name
- NCT03445065
- Testing
- Eversense XL CGM System, Usual SMBG or FGM device used by participants
- Where
- 20 sites in France
- Volunteers
- 239 people
- Sponsor
- Hoffmann-La Roche
Type 2 Diabetes Mellitus
Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes
The purpose of this study is to examine the effect CGM (continuous glucose monitoring) has on subjects with type 2 diabetes. It is anticipated that patients using the device will obtain tighter control of their blood sugars…
- Trial name
- DexlonT2 (NCT01341067)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Rocky Mountain Diabetes and Osteoporosis Center
Diabetes Mellitus
Evaluation of the Accuracy of an Implanted Glucose Sensor
The purpose of this clinical investigation is to evaluate the accuracy of the Senseonics Continuous Glucose Monitoring System (Senseonics CGM System) measurements when compared with reference standard measurements The…
- Trial name
- PRECISEII (NCT02647905)
- Testing
- Continuous Glucose Monitoring System
- Where
- 9 sites in United States
- Volunteers
- 90 people
- Sponsor
- Senseonics, Inc.
Type 2 Diabetes
A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)
This study is being done to evaluate glycemic control in participants with type 2 diabetes who are taking mealtime insulin LY900014 in combination with long-acting insulin glargine.
- Trial name
- NCT04605991
- Testing
- LY900014, Insulin Glargine
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 187 people
- Sponsor
- Eli Lilly and Company
Diabetes
New Generation Enlite Accuracy Study
The trial will investigate the accuracy and performance of a new sensor for continuous glucose monitoring (CGM), the (new generation) Enlite, CE-marked in 2013, in conjunction with the new Medtronic 640G system components.
- Trial name
- NCT02423798
- Testing
- Glucose sensor (Enlite)
- Volunteers
- 24 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus Type 2
Vildagliptin vs Sitagliptin add-on to Insulin - Impact on Glycemic Profile and Correlation of Hypoglycemic Episodes and Heart Function
Vildagliptin and Sitagliptin both belong to the class of DPP-4 inhibitors, but differ in their pharmacokinetic profile as well as in their approved application (Vildagliptin, 2x 50 mg daily, Sitagliptin, 1x 100 mg daily).
- Trial name
- CGM-VISIT (NCT01686932)
- Testing
- Vildagliptin, Sitagliptin
- Where
- 11 sites in Germany
- Volunteers
- 51 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes, Diabetes Mellitus
Biolinq Safety and Effectiveness Trial
The primary objective of the study is to evaluate the safety and effectiveness of the Biolinq MicroArray Intradermal Continuous Glucose Biowearable System, which is intended to be worn for up to five (5) days (up to 120 hours) in…
- Trial name
- NCT06229743
- Testing
- Biolinq System
- Where
- 6 sites in United States
- Volunteers
- 247 people
- Sponsor
- Biolinq Inc.
Diabetes Mellitus
A Pivotal Study to Evaluate Guardian™ Connect CGM System Performance in China
The purpose of this study is to demonstrate the performance and safety of the Guardian™ Sensor (3) over 170 hours (7 days) when inserted in the abdomen used in subjects age 14 - 75 years with the Guardian™ Connect System.
- Trial name
- NCT03710083
- Testing
- Guardian™ Sensor (3)
- Where
- 3 sites in China
- Volunteers
- 72 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
An Inpatient Performance Evaluation of a New Subcutaneous Glucose Sensor
The purpose of the study is to assess the performance of a new subcutaneous glucose sensor over a seven-day sensor life when used with currently marketed Medtronic Diabetes devices.
- Trial name
- NCT01112696
- Testing
- Sensor wear
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Type 1
INTERPRET - International Report on Routine Practice of Sensor-enabled Pump Therapy
The aim of the project is to document the international routine practice in sensor usage in patients treated with sensor-augmented pump therapy and to assess which variables (e.g.
- Trial name
- NCT00790088
- Where
- 26 sites in Austria, Belgium and 12 more
- Volunteers
- 274 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes
Safety and Effectiveness of the MiniMed™ 780G System With DS5 CGM
The purpose of this study is to confirm the safety and effectiveness of the MiniMed 780G insulin pump used in combination with the DS5 CGM in type 1 diabetes adult and pediatric subjects in a home setting.
- Trial name
- NCT05714059
- Testing
- Insulin Pump with Continuous Glucose Monitoring
- Where
- 23 sites in United States
- Volunteers
- 250 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus
Observational Study to Evaluate the Effectiveness and Safety of the Dexcom G4 Continuous Glucose Monitoring System in Pediatrics
The purpose of this study is to evaluate the effectiveness and safety of the Dexcom G4 System when used as an adjuvant to blood glucose testing over a 7-day period in people 2 to 17 years-old with diabetes mellitus.
- Trial name
- NCT02363907
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- DexCom, Inc.
Type 1 Diabetes
Use of the Paradigm 722 System to Improve Glycemic Control in Adult and Adolescent Subjects With Type 1 Diabetes
The purpose of this study is to determine whether Type 1 Diabetic subjects using the Paradigm 722 System, which is a glucose sensor-augmented insulin pump, can improve glycemic control when compared to subjects using the Paradigm…
- Trial name
- STAR1 (NCT00211510)
- Testing
- Paradigm 722 sensor augmented pump, Paradigm 715 insulin pump
- Where
- 7 sites in United States
- Volunteers
- 146 people
- Sponsor
- Medtronic MiniMed, Inc.
Type2 Diabetes
Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics - (Protocol 3)
This study allows Type 2 diabetics to receive feedback from a continuous glucose monitor (CGM) as part of an educational program designed to help them better manage their glucose levels.
- Trial name
- CGM_IRB-3 (NCT03290768)
- Testing
- Continuous Glucose Monitor (CGM), Activity Tracker, Coaching
- Where
- United States
- Volunteers
- 358 people
- Sponsor
- Savvysherpa, Inc.
Diabetes, Diabetes Mellitus, Type 1
A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes
This trial is conducted in the United States of America (USA). The aim of this trial is to compare the efficacy of insulin decludec with insulin glargine on glycaemic control using continuous glucose monitoring in patients with…
- Trial name
- NCT01569841
- Testing
- insulin degludec, insulin glargine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)
The purpose of this study is to assess the effects of administration of canagliflozin 100 mg and 300 mg, compared with placebo as an addition to insulin therapy for the treatment of Type 1 Diabetes Mellitus (T1DM).
- Trial name
- NCT02139943
- Testing
- Canagliflozin 100 mg, Canagliflozin 300 mg
- Where
- 53 sites in United States, Canada
- Volunteers
- 352 people
- Sponsor
- Janssen Research & Development, LLC
Diabetes
Routine Use of Sensor-Augmented Pump Therapy - a Follow up Study
The aim of this study is to document the routine practice in continuous glucose monitoring (CGM) in patients treated with sensor-augmented pump therapy and to assess clinical outcome (HbA1c) before the start of the sensor use to…
- Trial name
- NCT01451372
- Where
- Sweden
- Volunteers
- 69 people
- Sponsor
- Medtronic MiniMed, Inc.